What is it about?
Cisplatin is one of the world's most widely used chemotherapy drugs, but it has traditionally been thought to work mainly by causing DNA damage that triggers apoptosis—a form of programmed cell death. In this study, we show that cisplatin actually activates multiple cell death programs simultaneously, including apoptosis, necroptosis, pyroptosis, and ferroptosis. Using cancer cell lines, mouse tumor models, and human oral cancer specimens collected before and after cisplatin treatment, we found that these different death pathways occur together rather than independently. Among them, pyroptosis and ferroptosis were particularly prominent, suggesting that cisplatin not only kills tumor cells directly but also promotes inflammatory forms of cell death that may stimulate anti-tumor immune responses. These findings provide a more complete picture of how cisplatin works and explain why it often performs particularly well when combined with immunotherapy.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
For decades, cisplatin has been viewed primarily as a DNA-damaging drug that induces apoptosis. Our findings challenge this traditional view by demonstrating that cisplatin orchestrates a coordinated network of multiple programmed cell death pathways. This has several important implications: a) It provides a new biological framework for understanding why cisplatin remains highly effective against many cancers. b) It identifies pyroptosis and ferroptosis as major contributors to cisplatin's anti-tumor activity, highlighting their potential roles in stimulating anti-cancer immunity. c) It offers a mechanistic explanation for the clinical success of combining cisplatin with immune checkpoint inhibitors. d) It suggests that future therapies could intentionally enhance specific immunogenic cell death pathways to improve treatment outcomes while overcoming resistance. Rather than considering each death pathway separately, our work supports the concept that successful chemotherapy can arise from the coordinated activation of multiple complementary cell death mechanisms.
Perspectives
This study establishes a new conceptual framework in which cisplatin functions as a master coordinator of multiple programmed cell death programs rather than as a simple inducer of apoptosis. Several important questions now emerge: a) What molecular mechanisms determine how tumor cells choose between different cell death pathways? b) Can pyroptosis and ferroptosis be selectively amplified to improve anti-tumor immunity without increasing toxicity? c) Which biomarkers can identify patients most likely to benefit from therapies that promote immunogenic cell death? d) Can new combination treatments—including immune checkpoint inhibitors, ferroptosis-inducing agents, or pyroptosis-targeting approaches—further improve the clinical efficacy of cisplatin? Answering these questions could enable the next generation of precision chemotherapy strategies that not only eliminate tumor cells more effectively but also harness the patient's immune system to produce more durable cancer control.
Xiaodong Feng
West China School of Stomatology, Sichuan University
Read the Original
This page is a summary of: Synergistic Cell Death: Cisplatin Inflames Tumors by Coordinating Multiple Death Programs, BIOCELL, January 2026, Tsinghua University Press,
DOI: 10.32604/biocell.2026.075437.
You can read the full text:
Contributors
The following have contributed to this page
